Therapeutics of Neurotransmitters in Alzheimer's Disease.
Therapeutics of Neurotransmitters in Alzheimer's Disease.
复制标题
DOI：
10.3233/jad-161118
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Reddy PH
中科院分区：
文献类型：
--
作者：
Kandimalla R;Reddy PH
阿尔茨海默病（Alzheimer's disease，AD）是一种进行性神经退行性疾病，以记忆丧失、多种认知功能障碍以及人格和行为改变为特征。几十年的研究发现，疾病过程中除了β淀粉样蛋白（Aβ）和磷酸化tau蛋白的形成和积累外，还涉及多种细胞变化，包括突触损伤、线粒体异常和炎症反应。尽管在理解神经递质在AD的进展和发病机制中的影响方面已经取得了巨大的进展，但是我们仍然没有与神经递质相关的药物分子，其可以延缓老年个体的疾病过程和/或恢复AD患者的认知功能。我们的文章的目的是评估神经递质研究的最新进展，使用AD的细胞和小鼠模型。我们还更新了AD中使用神经递质激动剂/拮抗剂的临床试验的当前状态。
Alzheimer’s disease (AD) is a progressive neurodegenerative disease, characterized by the loss of memory, multiple cognitive impairments and changes in the personality and behavior. Several decades of intense research have revealed that multiple cellular changes are involved in disease process, including synaptic damage, mitochondrial abnormalities and inflammatory responses, in addition to formation and accumulation of amyloid-β (Aβ) and phosphorylated tau. Although tremendous progress has been made in understanding the impact of neurotransmitters in the progression and pathogenesis of AD, we still do not have a drug molecule associated with neurotransmitter(s) that can delay disease process in elderly individuals and/or restore cognitive functions in AD patients. The purpose of our article is to assess the latest developments in neurotransmitters research using cell and mouse models of AD. We also updated the current status of clinical trials using neurotransmitters’ agonists/antagonists in AD.